新闻Juncell attended event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Jun 1st '26.SHANGHAI, June 3, 2026 /PRNewswire/ - On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Lu Si from Peking University Cancer Hospital presented the results of a Pivotal Phase 2 clinical study (MIZAR-003) conducted in China evaluating the efficacy and safety of GC101 TIL therapy (Nolgileucel), developed by Shanghai Juncell Therapeutics Co., Ltd. for PD-1 antibody failed patients with advanced melanoma.
新闻Juncell attends event ASGCT Annual Meeting 2025.Juncell Therapeutics announces data on feeder-free IL-2-Independent TIL manufacturing process at ASGCT Annual Meeting 2025.
新闻Juncell receives award Disruptive Technology Innovation Competition.Juncell Therapeutics wins the highest award in the national Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology.
